LifeMD annual r&d spending
2015
2022
2023
2024
2025
LifeMD R&D Spending Growth & History (LFMD)
LifeMD's r&d spending was $7.3M for fiscal 2025.
View full LifeMD company overviewLifeMD annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.3M | $488,792 | +7.13% |
| 2024 | 2024-12-31 | $6.9M | $796,492 | +13.14% |
| 2023 | 2023-12-31 | $6.1M | $3.1M | +104.04% |
| 2022 | 2022-12-31 | $3.0M | — | — |
| 2015 | 2015-12-31 | $23,925 | — | — |
LifeMD quarterly r&d spending
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | −$31,627 | −1.73% |
| Q1 2026 | 2026-03-31 | $1.8M | — | — |
| Q4 2025 | 2025-12-31 | −$920,045 | — | — |
| Q3 2025 | 2025-09-30 | $2.8M | — | — |
| Q2 2025 | 2025-06-30 | $1.8M | — | — |
LifeMD r&d spending trends
Between the periods ended 2015-12-31 and 2025-12-31, LifeMD's r&d spending increased from $23,925 to $7.3M, a change of $7.3M. The latest reported quarter, Q2 2026, shows $1.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LifeMD source filings ↗